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Protein despite Deficiencies in both Receptor Recognition and
Fusion Promotion
Jianrong Li,1 Edward Quinlan,1,2 Anne Mirza,1 and Ronald M. Iorio1*
Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Worcester,
Massachusetts 01655-0122,1 and Department of Biology and Biotechnology, Worcester Polytechnic
Institute, Worcester, Massachusetts 016092
Received 10 November 2003/Accepted 29 December 2003
The Newcastle disease virus (NDV) hemagglutinin-neuraminidase (HN) protein mediates attachment to
cellular receptors. The fusion (F) protein promotes viral entry and spread. However, fusion is dependent on a
virus-specific interaction between the two proteins that can be detected at the cell surface by a coimmunopre-
cipitation assay. A point mutation of I175E in the neuraminidase (NA) active site converts the HN of the
Australia-Victoria isolate of the virus to a form that can interact with the F protein despite negligible receptor
recognition and fusion-promoting activities. Thus, I175E-HN could represent a fusion intermediate in which
HN and F are associated and primed for the promotion of fusion. Both the attachment and fusion-promoting
activities of this mutant HN protein can be rescued either by NA activity contributed by another HN protein
or by a set of four substitutions at the dimer interface. These substitutions were identified by the evaluation
of chimeras composed of segments from HN proteins derived from two different NDV strains. These findings
suggest that the I175E substitution converts HN to an F-interactive form, but it is one for which receptor
binding is still required for fusion promotion. The data also indicate that the integrity of the HN dimer
interface is critical to its receptor recognition activity.
The Newcastle disease virus (NDV) hemagglutinin-neura-
minidase (HN) is a multifunctional, type II membrane glyco-
protein. It exists at the surface of virions and virus-infected
cells as a tetrameric spike structure, consisting of a long, mem-
brane-proximal stalk region that supports a terminal globular
domain. The latter region of the spike is responsible for HNs
recognition of sialic acid-containing receptors as well as its
neuraminidase (NA) activity, which cleaves sialic acid from
both soluble and membrane-bound glycoconjugates (18). All
of the antibody binding sites on the protein also reside in the
globular domain (21).
Several hundred strains of NDV have been isolated from all
over the world. The X-ray crystallographic structures of the
globular domain of the HN from one of these, the Kansas
strain, as well as the protein complexed with sialic acid or an
inhibitor of NA, have been solved (3). These structures suggest
that the attachment and NA activities of HN are mediated by
a single sialic acid binding site in two different conformations.
Consistent with this, substitutions for several active site resi-
dues abolish both attachment and NA (3).
Similarly, substitutions for residues in the NA active site of
the HN from the Australia-Victoria (AV) isolate of NDV
(NDV-AV) also result in the loss of detectable attachment and
NA (11). These substitutions include I175E, D198R, K236R,
Y526L, and E547Q. However, our laboratory has shown that
the attachment activity of each of these receptor recognition-
deficient mutants can be partially rescued by providing NA
activity (11). Clearly, this is inconsistent with the existence of a
single site for both attachment and NA. Rather, it suggests that
the deficiency in receptor binding exhibited by these mutants is
secondary to the lack of NA and that attachment and NA are
defined by distinct sites.
In most paramyxoviruses, HN possesses a third function. It is
required for the conversion of the second viral surface glyco-
protein, the fusion (F) protein, to its active form (reviewed in
reference 18). This fusion activation requires a virus-specific
interaction between the two proteins, the specificity of which is
determined by a domain defined primarily by the stalk region
of the HN spike, as shown by the analysis of chimeras com-
posed of domains from heterologous HN proteins (5, 32, 33).
A role for the HN stalk in fusion is also supported by the
diminished fusogenic activity exhibited by HN proteins carry-
ing point mutations in this region (4, 25, 27, 30). The existence
of an HN-F interaction is supported by the coimmunoprecipi-
tation of the two proteins from the surface of both virus-
infected and HN-F-cotransfected cells (4).
Our laboratory has shown that attachment-deficient NDV-
AV HN, carrying substitutions for the catalytic aspartic acid,
D198, is also fusion deficient and fails to interact with F at the
cell surface in coimmunoprecipitation assays (4). This result is
consistent with a mechanism for fusion in which receptor rec-
ognition by the globular domain of HN is the trigger for the
HN-F interaction and fusion (17). However, the relationships
among receptor recognition, HN structure, the HN-F interac-
tion, and fusion are all still poorly understood.
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Certain substitutions in the active site of the HN protein
from the Kansas strain of NDV are capable of separating
fusion from receptor recognition. Specifically, E401D and
Y526F or L substitutions induce enhanced fusion promotion,
despite negligible hemadsorption (HAd) activity. Similarly,
I175E-mutated HN promotes fusion 50% more effectively than
the wild-type (wt) protein, despite having 60% less HAd activ-
ity (1). To explain this phenomenon, it was postulated that
these substitutions induce structural changes in HN that mimic
those that occur upon receptor binding. These structural
changes may involve alterations in the structure of the HN
dimer interface, thereby triggering the HN-mediated fusion-
activation of the F protein.
In contrast to I175E-mutated HN from NDV-Kansas, HN
from the NDV-AV isolate carrying the same substitution ex-
hibits negligible HAd and NA activities (11). We show here
that this mutant HN also fails to promote fusion. Despite this
lack of function, I175E-AV HN efficiently interacts with the
homologous F protein. Both the attachment (11) and fusion-
promoting activities of the mutated protein can be rescued by
providing NA activity. We have constructed HN chimeras com-
posed of various segments from the HN proteins of NDV-AV
and strain Kansas-Leavenworth (NDV-L). The latter is closely
related to the Kansas strain used in the above-mentioned crys-
tallographic and mutational studies. Analyses of these chime-
ras and site-directed mutants confirm that four residues at the
dimer interface are responsible for the phenotypic differences
between the I175E-mutated forms of HN from the two strains.
Based on these findings, we propose that I175E-mutated
NDV-AV HN represents a form of the protein that is capable
of interacting with the F protein in the absence of receptor
recognition. This form of HN is still incapable of triggering the
fusion-activation of F due to its inability to bind receptors as a
result of amino acid differences localized to the dimer inter-
face. These findings also argue for the importance of the struc-
ture of the dimer interface for the receptor recognition activity
of HN.
MATERIALS AND METHODS
Recombinant plasmids. Construction of the NDV-AV HN and F recombinant
pBluescript SK() (Stratagene Cloning Systems, La Jolla, Calif.) expression
vectors has been described previously (20). The HN of B1-Hitchner (NDV-B1)
was a gift of Kemal Karaca (Megan Health, Inc., St. Louis, Mo.). It was released
from the vector in which it was supplied by XhoI digestion and ligated into the
pBSK plasmid cut with the same enzyme. The Beaudette C (NDV-BC) HN gene
was a gift of Peter Emmerson (University of Newcastle Upon Tyne, Newcastle
Upon Tyne, England). It was released from the vector in which it was supplied
by digestion with XbaI and SacI and ligated into pBSK cut with the same
enzymes.
The HN gene of NDV-L was generated by reverse transcription-PCR. Viral
RNA was extracted by Trizol LS reagent (Invitrogen, Carlsbad, Calif.). First-
strand cDNA was synthesized with Superscript II RNase H reverse transcrip-
tase (Invitrogen). The HN gene was amplified by the Expand High-Fidelity PCR
system (Roche Diagnostics, Indianapolis, Ind.), with primers P1 (5-CCCAAG
CTTACCTCCGTTCTACCGCTTCA-3) and P2 (5-GCTCTAGAGCTCGCA
CCGGCATTCAGTT-3). The HindIII and XbaI sites, respectively, are under-
lined in the primer sequences. The HN gene was gel purified, digested with
HindIII and XbaI and cloned into pBSK at the same sites, resulting in plasmid
pBSK-L-HN. Three independent clones were sequenced at the University of
Massachusetts Nucleic Acid Facility. The sequence of L-HN used in this study is
98.3% homologous to that of the Kansas isolate used to generate the crystals of
the protein (3). There are a total of 10 amino acid differences between the two
proteins, 5 of which are in the tail and transmembrane domains. Amino acid
differences in the ectodomain between L-HN and Kansas-HN are D for N144, V
for A271, S for G310, E for G332, and A for V571. Only the last four amino acid
differences reside in the globular domain of the protein.
wt L-HN and all mutants and chimeras derived from it were mutated to have
a W123C mutation. Cysteine at this position mediates disulfide-linked ho-
modimer formation, analogous to AV-HN, as confirmed by sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis (21). This was done for two
reasons. First, Crennell et al. (3) have reported that this disulfide bond results in
higher fusion-promoting activity, a finding that we have confirmed (data not
shown). Second, in comparing the functional activities of AV-HN/L-HN chime-
ras with different stalk regions, we thought it important that those stalk regions
have the same quaternary structure. The W123C mutation was also introduced
into the HN of NDV-BC and NDV-B1, inducing disulfide-linked dimer forma-
tion in proteins that are also normally non-disulfide-linked (28).
Construction of pCAGGS-HN and pCAGGS-F expression vectors. AV-HN
and mutants derived from it were released from pBSK by digestion with XbaI
and SacI, blunt-ended by DNA polymerase I large (Klenow) fragment (New
England Biolabs, Beverly, Mass.), and then cloned into the EcoRI and SacI sites
of pCAGGS, also blunted by Klenow. L-HN was released from pBSK by diges-
tion with HindIII and XhoI, blunted by Klenow, and cloned into the EcoRI and
XhoI sites of pCAGGS, also blunt-ended by Klenow. AV-F was released from
pBSK by digestion with XhoI and cloned into pCAGGS, which had been di-
gested by the same enzyme. The correct orientation of each of the inserts was
verified by enzyme digestion and sequencing.
Site-directed mutagenesis. Site-directed mutagenesis was performed as de-
scribed previously (2), with mutagenesis primers obtained from Integrated DNA
Technologies, Inc. (Coralville, Iowa). Identification of mutants was facilitated by
screening for the presence of a unique restriction enzyme site introduced by a
silent mutation in the mutagenic primer. The presence of the desired mutation
was verified by sequencing of double-stranded DNA, with the Sequenase plasmid
sequencing kit (United States Biochemical, Cleveland, Ohio), according to pro-
tocols provided by the company. Multiple clones were characterized for each
substitution.
Construction of chimeric HN genes. Using unique, homologous restriction
enzyme sites in the AV-HN and L-HN genes, an initial pair of chimeric HN
genes (CH-A and CH-B) was constructed (Fig. 1). Taking advantage of NspI
sites in the HN gene and in the vector, C-terminal fragments of the two HN
genes were isolated. The fragments were ligated into the heterologous HN gene
previously digested with the same enzyme. This resulted in chimeras CH-A and
CH-B, in which the N-terminal 344 residues are derived from AV and L HN,
respectively, and the rest of the protein is derived from the heterologous HN
protein.
To exchange the N-terminal 167 amino acids of AV-HN and L-HN, we took
advantage of a unique EcoNI site in L-HN. The same site was introduced into
AV-HN by using the primer 5-GAATTTTATACCAGCACCTACTACAGGA
TCAG-3. This did not result in any amino acid changes in the AV-HN protein.
The mutated HN genes were cut with HindIII and EcoNI, and the fragments
were ligated into the heterologous HN gene that had been digested with the
same enzymes to produce chimeras CH-C and CH-D.
To exchange the amino acids between residues 168 and 344 in AV-HN and
L-HN, chimeras CH-C and CH-D were cut with NspI and the fragments were
ligated into the heterologous chimeric HN gene previously digested with the
same enzyme. This resulted in chimeras CH-E and CH-F.
To exchange the amino acids between residues 168 and 288 in AV-HN and
L-HN, chimeras CH-C and CH-D were cut with AatII and SacI and the frag-
ments were ligated into the heterologous, chimeric HN genes that had been
digested with the same enzymes. This resulted in chimeras CH-G and CH-H.
To exchange the amino acids between residues 168 and 244 in AV-HN and
L-HN, we took advantage of unique, homologous Bsu36I sites in the two genes.
Chimeras CH-C and CH-D were cut with this enzyme and SacI, and the frag-
ments were ligated into the heterologous HN genes that had been digested with
the same enzymes, resulting in chimeras CH-I and CH-J.
Transient expression systems. wt and mutant HN proteins were expressed in
BHK-21 cells (American Type Culture Collection, Manassas, Va.) by using the
vaccinia-T7 RNA polymerase expression system (6). All experiments, except NA
assays, were performed in 35-mm-diameter plates seeded a day earlier at 4 105
cells/well. Maintenance of cells, infection with the vaccinia recombinant, and
transfection were performed as described previously (2), with 1 g of each
plasmid for transfection.
HN and F proteins in the pCAGGS vector were expressed in HeLa cells that
were seeded in six-well plates a day earlier at 4  105 cells/well. DNA (1.5
g/well) was transfected into the cells with PolyFect transfection agent (Qiagen
Inc., Valencia, Calif.) according to protocols provided by the company. Assays
were performed 48 h posttransfection.
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Cell surface expression. The amount of each HN mutant at the cell surface
was determined by flow cytometry with a mixture of monoclonal antibodies
(MAbs), including at least three that recognize epitopes conserved in the glob-
ular domains of each of the HN proteins used in this study (9, 10, 14–16).
HAd assay. The HAd activity of HN proteins was assayed by the ability of
expressed proteins to adsorb guinea pig erythrocytes (Crane Laboratories, Syr-
acuse, N.Y.). HN-expressing monolayers were incubated for 30 min at 4°C with
a 2% suspension of erythrocytes in phosphate-buffered saline (PBS) supple-
mented with 1% CaCl2 and MgCl2. After extensive washing, adsorbed erythro-
cytes were lysed in 50 mM NH4Cl and the lysate was clarified by centrifugation.
HAd activity was quantitated by measuring the absorbance at 540 nm minus the
background obtained with vector-expressing cells.
NA assay. NA assays were performed on 12-well (22.6-mm diameter) plates
seeded a day earlier at 1.6  105 cells/well and transfected with 0.5 g of DNA.
Monolayers were incubated at 37°C for 20 min with 0.5 ml of 625-g/ml
neuraminlactose (Sigma Chemical Co., St. Louis, Mo.) in 0.1 M sodium acetate
(pH 6), and NA activity was determined as described previously (20). Data were
corrected for differences in cell surface expression.
Content-mixing assay for fusion. The ability of the mutated HN proteins to
complement the F protein in the promotion of fusion was quantitated by a
content-mixing assay which measures -galactosidase activity in target cells fol-
lowing fusion induced by HN-F-expressing effector cells (2).
Rescue of fusion-promoting activity of HN mutants by coexpression with
another HN protein. Using a modification of an assay described previously (11),
we determined whether the fusion-promoting activity of functionally deficient
mutants could be rescued through the contribution of NA activity by another
coexpressed HN protein. The HN protein chosen for these experiments was a
human parainfluenza virus type 3 (hPIV3)-NDV chimera, called CH1(11) (5).
This chimera has 152 N-terminal amino acids derived from hPIV3 HN and does
not oligomerize with NDV HN. The rest of the protein, including the entire
globular domain, is derived from NDV-AV HN. It retains approximately 10% of
wt NDV-AV HN NA activity.
To make it possible to selectively inhibit the attachment activity of the chi-
mera, an E347G substitution was introduced into each of the functionally defi-
cient mutants as well as the control wt protein. This substitution renders the
protein unrecognizable by MAbs to antigenic site 14, which inhibits the attach-
ment and fusion activities of the rescuing chimera (9, 14). The substitution itself
has no effect on HN function (9, 16).
To determine the fusion-promoting activity of mutants coexpressed with
CH1(11), the content-mixing assay was used. The HN-F-expressing cells (105
cells in 100 l of medium) were treated with 200 g of MAb 14f for 30 min at
37°C prior to mixing with the target cells containing the -galactosidase gene.
This antibody completely blocks the attachment and fusion activities of the
chimera but has no effect on the mutants carrying the E347G substitution. The
HAd and fusion-promoting activities of the monolayers were then determined.
The data are expressed as percentages of the activities obtained with monolayers
expressing wt HN carrying the E347G substitution after subtraction of the back-
ground from vector-expressing cells.
Coimmunoprecipitation assay. The ability of wt and mutated HN proteins to
interact with F at the surface of transfected BHK cells was assayed at 16 h
FIG. 1. Construction of chimeras of HN glycoproteins of the AV and L strains of NDV. Chimeras were constructed between the HN of the
AV strain (white bars) and that of the L strain (stippled bars). This was made possible by the use of unique restriction enzyme sites in the two genes
corresponding to amino acid residues 167, 243, 287, and 344. Residue 175 in each protein is indicated by an asterisk. Residues that are not
conserved between the two proteins are indicated by dots between the sequences of the two parent proteins. Also, L-HN has six additional residues
at its C terminus relative to AV-HN.
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posttransfection, by a modification of a coimmunoprecipitation assay described
previously (4). Because the amount of the F protein immunoprecipitated from
the cell surface is greatly affected by the extent of fusion, we used a cleavage site
mutant form of F for which cleavage activation and fusion are dependent on
trypsin treatment. Our laboratory has previously shown that this mutated form of
F interacts efficiently with the HN protein in the coimmunoprecipitation assay
(4).
Equal numbers of cells were starved and labeled as described previously (4)
and washed three times with cold PBS supplemented with 0.1 mM CaCl2 and 1
mM MgCl2. Cell surface proteins were biotinylated with sulfo-NHS-SS-biotin
(Pierce, Rockford, Ill.) for 30 min in the cold with gentle agitation, followed by
removal of the excess reagent by washing twice with PBS supplemented with 0.1
mM CaCl2 and 1 mM MgCl2. Cells were lysed in DH buffer (50 mM HEPES [pH
7.2], 10 mM dodecyl--D maltoside [United States Biochemical], 150 mM NaCl)
containing 1 mM phenylmethylsulfonyl fluoride for 45 min in the cold. Lysates
were split into two aliquots and immunoprecipitated for 90 min in the cold with
either a MAb specific for the F protein only or this MAb plus a mixture of
anti-HN MAbs. After centrifugation, the supernatant was added to protein
A-agarose beads and incubated for 1 h in the cold, after which immunobeads
were washed four times with DH buffer. Bound proteins were released by boiling
for 5 min in 10 l of 10% SDS. Samples were brought up to 0.5 ml with DH
buffer, and the beads were pelleted. Proteins were reprecipitated from the
supernatant with streptavidin beads, and the immunoprecipitates were displayed
by SDS-polyacrylamide gel electrophoresis. The percentage of total cell surface
HN that coimmunoprecipitated with F was quantified with a Bio-Rad Fluor-S
multi-imager (Hercules, Calif.). Cells expressing vector, HN, or cleavage site
mutant F alone served as controls to ensure that the coimmunoprecipitation of
HN by the F antibody occurred only through its interaction with the F protein.
RESULTS
Attachment-deficient mutants lack detectable fusion-pro-
moting activity. It was previously demonstrated that several
substitutions in the NA active site completely abolish the HAd
and NA activities of NDV AV-HN, despite efficient expression
of the protein at the cell surface. These mutations include
I175E, D198R, K236R, Y526L, and E547Q (4, 11). D198R-
mutated HN is also unable to complement the homologous F
protein in the promotion of fusion (4). We have now examined
the fusion-promoting capability of HN carrying each of the
other active site mutations. Similar to D198R-HN, none of
these mutants, including I175E-AV-HN, exhibits significant
fusion-promoting activity. All promote fusion less than 3% of
that of wt HN. Results for each substitution mutant are as
follows (results are percentages of wt AV-HN): I175E, 1.9 
0.7; D198R, 1.1  0.1; K236R, 1.2  0.6; E547Q, 2.7  0.2. No
fusion was detected for Y526L.
I175E-mutated AV-HN interacts with F, despite its lack of
attachment and fusion-promoting activities. To assay for the
presence of an interaction between the HN and F proteins at
the cell surface, we use a coimmunoprecipitation assay that
determines the amount of HN brought down through its in-
teraction with F by an antibody to the latter. Figure 2A shows
the coimmunoprecipitation results for wt AV-HN and F. To
determine the total amount of each protein present at the cell
surface, each set of monolayers was immunoprecipitated with
a mixture of anti-HN MAbs and an anti-F MAb (the first lane
in each set). The percentage of cell surface HN that interacts
with F is quantitated by determining the amount of HN that
coimmunoprecipitates with F, with only the anti-F MAb (the
second lane in each set). The last lane in this gel shows that a
protein comigrating with HN is coimmunoprecipitated by the F
antibody from the surface of cells coexpressing the HN and F
proteins.
FIG. 2. Coimmunoprecipitation of AV-HN and fusion-deficient mutants derived from it with the homologous F protein. Equal numbers of cells
were transfected as indicated. The F protein used in these experiments is a cleavage site mutant of NDV-AV F that is not cleaved and does not
promote fusion (4). After 16 h, the cells were starved and labeled as described previously (4). The cell surface proteins were biotinylated, and the
cells were lysed by treatment with dodecyl maltoside. The lysate was split into two aliquots and immunoprecipitated with either a combination of
an anti-F antibody and a mixture of anti-HN antibodies (the first lane in each pair) or an anti-F antibody alone (the second lane in each pair). The
gels in panels A and C were run under reducing conditions. The gel in panel B was run under nonreducing conditions. , present; , absent; vec,
vector; HNdi, HN dimer.
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To verify that the coimmunoprecipitated protein is authentic
HN, a duplicate experiment of that in Fig. 2A was performed
and the gel was run under nonreducing conditions (Fig. 2B).
Under these conditions, the protein coimmunoprecipitated
with F comigrates near the top of the gel with the disulfide-
linked dimer of HN precipitated by the anti-HN antibody. This
verifies that the protein coimmunoprecipitating with F is HN.
The mean of five experiments identical to that shown in Fig.
2A reveals that the percentage of total cell surface HN that
coimmunoprecipitates with F in this assay is 32.6%  7.6%.
Critical controls for this experiment show that HN is not
brought down by the F antibody in the absence of the F protein
and is not present in precipitates from cells expressing only the
F protein (Fig. 2A). These controls ensure that the coimmu-
noprecipitation of HN occurs only through its interaction with
F.
Figure 2C shows coimmunoprecipitation results for the
functionally deficient I175E, D198R, K236R, Y526L, and
E547Q mutated HN proteins. Consistent with previous find-
ings (4), D198R-HN does not interact with F in this assay.
Similarly, no interaction can be detected between the F protein
and HN carrying either the K236R or E547Q substitution. A
band comigrating with HN is barely detectable with Y526L
mutated HN, but it is less than 1% of the total amount of
Y526L mutated HN at the cell surface and is probably not
significant. However, I175E-HN does coimmunoprecipitate
with F. The mean of three determinations shows that 14.3% 
4.7% of the total amount of the mutant at the cell surface
coimmunoprecipitates with F. Again, this mutant HN-F inter-
action takes place despite negligible HAd, NA, and fusion.
The NA deficiency of each of the HN mutants is evident
from the slower migration rate of the F protein coexpressed
with any of the mutants, even I175E, compared to that of F
coexpressed with wt HN. F coexpressed with the mutants comi-
grates with F expressed in the absence of HN. The compara-
tively faster migration rate of F coexpressed with HN results
from the removal of sialic acid from its glycosyl groups medi-
ated by the wt HN NA activity, which is lacking in the mutated
proteins.
I175E-AV-HN is not dominant negative for fusion; its fu-
sion-promoting activity can be rescued by NA activity contrib-
uted by a coexpressed protein. Since the interaction between
I175E-HN and F results in a complex that is nonfusogenic, the
possibility exists that I175E mutated HN may be dominant
negative for fusion when coexpressed with the wt HN protein.
The mutated protein could tie up F protein spikes in a nonfu-
sogenic complex, precluding their association with wt F and
decreasing the extent of fusion. To test this possibility, we
cotransfected the mutant along with wt HN and F and stained
the monolayers for fusion. The presence of the mutant, even
up to a threefold excess over wt HN, has no effect on the extent
of fusion (data not shown).
The HAd activity of proteins carrying any of the above
substitutions in the NA active site, including I175E, can be
rescued by the contribution of NA either exogenously or by
coexpression with another protein (11). Thus, we have ex-
plored the possibility that the ability of these mutants to com-
plement the F protein in the promotion of fusion can also be
rescued in a similar fashion. To address this question, we have
used a modification of a chimera rescue assay described pre-
viously (11). In this assay, the attachment-deficient mutant is
coexpressed with an hPIV3-NDV HN chimera, whose attach-
ment and fusion-promoting activities are blocked by an NDV-
HN-specific MAb. The mutant carries an innocuous substitu-
tion that renders it unrecognizable by the inhibiting antibody.
In the content-mixing assay for fusion, the cells coexpressing
the attachment-deficient HN mutant, the rescuing chimera,
and NDV F are treated with the anti-HN inhibiting antibody
prior to mixing with the target cells to initiate fusion. This
ensures that any attachment and fusion in the system is medi-
ated through the rescue of the attachment and fusion activities
of the mutant.
The results of this experiment for the NDV-AV HN mutants
are shown in Fig. 3. As expected, none of the mutants mediates
a significant level of fusion in this assay. However, when each
mutant is coexpressed with the chimera, extensive fusion can
be detected. In the presence of the rescuing chimera,
I175E-HN promotes 54.8% of the positive control, whereas it
promotes only 3.1% of wt fusion in the absence of the chimera.
Similarly, by coexpression with the chimera, the other mutants,
D198R, K236R, Y526L and E547Q, gain the ability to promote
63.1, 75.9, 81.9, and 76.2% of wt HN fusion-promoting activity,
respectively, though they all promote less than 5% of wt fusion
in the absence of the chimera. Thus, each of the normally
fusion-deficient mutants gains the ability to promote highly
significant amounts of fusion via the contribution of NA from
a coexpressed HN protein.
Phenotypic differences between I175E-mutated AV-HN and
L-HN are not related to the use of different cells or expression
FIG. 3. Rescue of fusion-promoting activity of attachment and fu-
sion-deficient mutants by coexpression with an hPIV3-NDV HN chi-
mera. The figure shows the fusion-promoting activity exhibited by
NDV-AV mutants I175E, D198R, K236R, Y526L, and E547Q. The
mutated HN proteins carry an innocuous mutation (E347G) that ren-
ders them unrecognizable by an antibody to antigenic site 14. Cells
coexpressing the mutated HN protein, the rescuing chimera, and the
NDV F protein are pretreated for 30 min at room temperature with
200 g of site 14 antibody in 100 l of medium just before mixing with
the target cells in the reporter gene content-mixing assay. Data are
expressed as percentages of wt HN carrying the site 14 mutation and
treated in the same way. Each bar represents the average of the results
from at least four determinations. , plus; , without.
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systems. The phenotype of I175E-mutated AV-HN is quite
different from that of Kansas-HN carrying the same substitu-
tion (1). The latter retains 40% of the HAd activity and 13% of
the NA activity exhibited by the wt protein. Most importantly,
it promotes fusion approximately 50% more effectively than
the wt parent protein. To try to gain insight into the changes in
the structure of I175E-mutated AV-HN responsible for its
unique phenotype, we have compared it to the corresponding
mutated form of Kansas HN.
Possibilities that could account for the phenotypic difference
between AV-HN and Kansas-HN, both carrying I175E muta-
tions, are the use of different cells and/or expression systems.
The AV-HN study was performed with BHK cells with protein
expression driven by the vaccinia-T7 system (11). On the other
hand, the Kansas-HN data was generated with 293T (HAd and
NA) and HeLa (fusion) cells with the pCAGGS expression
plasmid, which uses the -chicken actin promoter (1).
The L strain of NDV is closely related to the Kansas isolate
used in the Connaris et al. (1) study, and its I175E mutated
form exhibits a phenotype similar to that of the Kansas HN
(Table 1). To determine whether the phenotypic differences
between the I175E mutated forms of AV-HN and L-HN are
related to the use of different expression systems and/or cells,
we have compared the activities of each mutant expressed in
BHK cells with the vaccinia-T7 system and in HeLa cells with
the pCAGGS expression system. Table 1 shows the cell surface
expression and HAd, NA, and fusion-promoting (with AV-F)
activities of each of the proteins expressed in both cell types.
I175E mutated AV-HN is functionally deficient whether it is
expressed in the vaccinia-T7-BHK system or in the pCAGGS-
HeLa system, promoting negligible levels of HAd, NA, and
fusion, despite efficient expression at the cell surface.
Similarly, expression of I175E mutated L-Kansas HN either
in BHK cells with the vaccinia-T7 system or in HeLa cells with
the pCAGGS system gave similar results (Table 1). The mu-
tant hemadsorbs approximately 50% of wt and exhibits 5 to
10% of wt NA activity in either system. Also, it promotes
fusion nearly 50% more efficiently than the wt protein in both
systems. These levels of activity are very similar to those pre-
viously reported with the pCAGGS-HeLa expression system
(1).
Figure 4 compares the extent of syncytium formation in
monolayers in which the wt AV-HN and L-HN proteins, as
well as the I175E mutated form of each, are coexpressed with
NDV F in the pBSK-BHK and pCAGGS-HeLa expression
systems. The two wt proteins promote significant amounts of
syncytium formation in either BHK or HeLa cells. Similarly,
I175E-L-HN promotes more fusion than its parent wt protein
in either system and monolayers expressing I175E-AV-HN are
indistinguishable from vector-expressing cells in either system.
Thus, the phenotypic differences between AV-HN and L-Kan-
sas HN, both carrying an I175E mutation, are not related to
the use of different expression systems or cells.
Functional activities of AV-HN/L-HN chimeras carrying the
I175E mutation. The data in Table 1 suggest that the effect of
the I175E mutation on HN function is strain specific, i.e.,
dependent on the HN background in which the mutation is
introduced. There are 52 amino acid differences between the
AV and L HN proteins (89.3% homology), scattered over the
entire length of the protein (Fig. 1). In addition, the L-HN
protein also has 6 more amino acids at its C terminus. To
identify those amino acid differences between the two proteins
that account for their phenotypic properties, we have con-
structed a series of chimeric HN proteins, all of which carry the
I175E mutation (Fig. 1). All chimeras in the series are ex-
pressed at the cell surface in amounts ranging between 82.5
and 112.1% of the wt protein (Fig. 5).
The HAd and NA activities of the chimeras are shown in
Fig. 6. CH-A has 318 residues at its N terminus derived from
I175E-AV-HN, and the rest of the protein is derived from
L-HN (Fig. 1). It has undetectable NA activity, similar to that
of I175E-AV HN, whereas the NA of CH-B is slightly higher,
4.7% of L-HN, similar to that of I175E-L-HN. Similar results
are found with respect to HAd and fusion. Chimera CH-A and
I175E-AV-HN exhibit similar low HAd activities, approxi-
mately 1% of wt AV-HN, although CH-A does promote mar-
ginally higher levels of fusion, 5.5% compared to 1.9% (Fig. 6).
CH-B is the reciprocal chimera with 318 N-terminal residues
from I175E mutated L-HN and the rest of the protein from
AV-HN. It has similar NA (4.2 versus 5.6%), HAd (44.4 versus
54.0%), and fusion activities (136.1 versus 138.8%) to wt L-HN
(Fig. 6). Thus, in both cases, the phenotype of the parent I175E
mutated protein segregates with the N-terminal segment. This
indicates that amino acids that lie C-terminal to residue 318 do
not play a role in the phenotypic differences between the I175E
mutated forms of AV-HN and L-HN.
Chimeras CH-C and CH-D address the possibility that the
N-terminal 167 residues of HN contribute to the phenotypic
differences between the I175E mutants. Chimera CH-C, with
167 residues at its N terminus derived from L-HN and the rest
of the protein from AV-HN, behaves like I175E mutated AV-
HN. It has barely detectable HAd and NA activities (Fig. 6)
and promotes fusion at only 4.4% of the wt level (Fig. 6).
Similarly, the reciprocal chimera CH-D exhibits a phenotype
very similar to that of I175E mutated L-HN (Fig. 6). Thus, data
from the analyses of chimeras A to D point to one or more
residues between 168 and 318 as being accountable for the
phenotypic differences between AV-HN and L-HN carrying
the I175E mutation.
To confirm this, we have constructed chimeras CH-E and
CH-F, in which only this central domain is derived from the
heterologous HN protein. As expected from the results ob-
tained with the first four chimeras in the series, CH-E, with
TABLE 1. Phenotypic difference between I175E mutated forms of
L-HN and AV-HN is not due to use of different cells or
expression systems
HN function
Result for mutant and cell type
I175E L-HNa 175E AV-HNb
BHKc HeLad BHK HeLa
Expression 91.3  8.1 93.7  7.8 84.1  12.9 89.5  10.6
HAd 54.0  2.8 51.7  6.1 0.7  0.9 0.8  0.3
NA 5.6  0.4 8.8  0.9 NDe ND
Fusion 138.8  12.6 146.0  6.4 1.9  0.7 1.5  0.4
a All data are expressed as percentages of wt L-HN.
b All data are expressed as percentages of wt AV-HN.
c Expression in BHK cells driven by the vaccinia-T7 system.
d Expression in HeLa cells with the pCAGGS expression system.
e ND, none detected.
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FIG. 4. Syncytium formation induced by wt AV and L HN and I175E mutated forms of the two proteins in BHK and HeLa cells with different
transient expression systems. Panels on the left show BHK cell monolayers, and panels on the right show HeLa cells. Except for the top two
monolayers, in which only vector is expressed, cells coexpress wt NDV-AV F with the indicated HN protein. At 22 h posttransfection, the
monolayers were fixed with methanol and stained with Giemsa stain.
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residues 168 to 318 derived from AV-HN, has a phenotype that
corresponds to that of I175E-AV-HN: 0.2% NA activity, 2.0%
HAd, and 5.3% fusion relative to wt AV HN (Fig. 6). Similarly,
CH-F, with the central 168 to 318 domain from L-HN and the
rest of the protein from AV-HN, exhibits a phenotype similar
to that of I175E-L-HN: approximately 4% NA, 40% HAd, and
approximately 125% fusion relative to the control (Fig. 6).
These findings confirm that the strain-specific phenotypic dif-
ferences in I175E mutated HN map to residues 168 to 318.
Two additional sets of chimeras with shorter central heter-
ologous domains were constructed. CH-G and CH-H have
only residues 168 to 287 derived from the heterologous HN
protein (Fig. 1). These chimeras behave very similarly to the
chimeras from which they were derived, CH-E and CH-F,
respectively (Fig. 6). CH-G has barely detectable HAd and NA
and fuses only 4.4% of the wt. Thus, it corresponds phenotyp-
ically to both CH-E and I175E-AV-HN. CH-H, with only res-
idues 168 to 287 derived from L-HN, has 4.5% NA, 53.2%
HAd, and 128.5% fusion relative to wt L-HN (Fig. 6). Thus,
this set of chimeras further maps the I175E-HN phenotype to
these 120 residues.
The final set of chimeras in the series includes CH-I and
CH-J (Fig. 1). These two chimeras have only residues 168 to
243 derived from the heterologous HN protein. As before, the
FIG. 5. Cell surface expression and antigenic integrity of I175E
mutated HN chimeras. The cell surface expression of the chimeras was
quantitated by flow cytometry, with a panel of at least 3 MAbs specific
for different antigenic sites on the globular domain of the protein. The
results shown represent the mean of the results from at least four
determinations.
FIG. 6. HAd, NA, and fusion-promoting activities of HN chimeras. The NA activity of each chimera was assayed at 22 h posttransfection by
determining the ability of each to cleave sialic acid from neuraminlactose. The NA data are corrected for differences in cell surface expression (Fig.
5) and are expressed as a percentage of the NA of the respective wt HN protein. They represent the means of the results from a minimum of three
determinations. The HAd activity was determined by the ability of the expressed proteins to hemadsorb guinea pig erythrocytes. For HAd activity,
the data represent the means of the results from at least four determinations. The ability to complement the wt NDV-AV F protein in the
promotion of fusion was determined by the content-mixing assay. Each value is the mean of the results from a minimum of three determinations.
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central heterologously derived segment determines the pheno-
type of these chimeras. CH-I, with an AV-HN heterologous
segment, exhibits an I175E-AV-HN-like phenotype, with HAd
and NA less than 1% and fusion only 5.8% of the wt. In
contrast, CH-J, with a heterologous domain from the L-HN
protein, exhibits a phenotype like I175E-L-HN. It has 4.2% of
wt NA activity but mediates both HAd and fusion extremely
well, 76.8 and 149.8% of the wt, respectively (Fig. 6). These
data map the residues responsible for the phenotypic differ-
ence between the I175E mutated HN proteins to residues 168
to 243, a domain consisting of 76 residues.
Phenotypic differences between I175E mutated AV and
L-HN are due to amino acid differences at four residues. Com-
parison of the sequences of AV-HN and L-HN between resi-
dues 168 and 243 reveals only four amino acid differences.
Residue 193 is a phenylalanine in AV-HN and a leucine in
L-HN. Residue 214 is a serine in AV-HN and a threonine in
L-HN. Residue 219 is a valine in AV-HN and an isoleucine in
L-HN. Lastly, residue 228 is an asparagine in AV-HN and a
serine in L-HN.
To evaluate the contribution of each of these amino acid
differences between the two strains to their phenotypic differ-
ences, we have mutated the residues at each position in I175E-
AV-HN to the residues found in L-HN and determined the
effect on HN function. Initially, mutations F193L and N228S
were introduced individually and S214T and V219I were in-
troduced in tandem. The properties of these mutants are listed
in Table 2. All three mutated proteins are efficiently expressed
at the cell surface. The N228S mutated protein is very similar
to the parent protein (I175E-AV-HN), with negligible HAd,
NA, and fusion activities. The F193L change and the S214T
and V219I changes do have some effect on the HAd and fusion
of I175E-AV-HN, each resulting in a 10-fold increase in HAd
and a 5-fold increase in fusion. However, these activities are
still much less than the HAd and fusion activities of I175E-L-
HN.
Next, the F193L, S214T, and V219I mutations were intro-
duced together into I175E-AV-HN. This triple mutant shows a
10-fold increase in HAd (12.8 versus 0.7%), NA (1.1 versus
0.1%), and fusion (28.5 versus 1.9%) relative to the parent
protein. However, only when all four mutations relative to
L-HN (F193L, S214T, V219I, and N228S) are introduced in
I175E-AV-HN does the protein acquire the phenotype of
I175E-L-HN. I175E-AV-HN carrying all four substitutions has
HAd (53.8 versus 54.0%), NA (6.0 versus 5.6%), and fusion
(141.6 versus 138.8%) activities that are remarkably similar to
those of I175E mutated L-HN. Thus, all four amino acid dif-
ferences between residues 168 and 243 in AV-HN and L-HN
together are responsible for the phenotypic differences be-
tween the two proteins. It is likely that the increased HAd and
fusion activities exhibited by the mutant are secondary effects
of the increased NA activity. In other words, HAd and fusion
are dependent on NA activity.
Strain comparisons confirm the importance of residues
T214, I219, and N228 to the high-fusion phenotype of I175E
mutated HN. Figure 7 compares the sequences of the HN
proteins of NDV strains AV, L, BC, and B1 between residues
168 and 243. With the lone exception of the tyrosine at position
203 in B1-HN, there is complete homology at all positions
except 193, 214, 219, and 228. In fact, B1-HN is completely
homologous to AV-HN at the latter three positions, whereas
BC-HN is completely homologous to L-HN at these three
residues. AV-HN is, thus far, unique among NDV strains in
having a phenylalanine at position 193 (26).
To confirm our findings with respect to the importance of
residues 214, 219, and 228 to the phenotype of I175E mutated
HN, we have created NDV-BC HN carrying an I175E substi-
tution and compared its phenotype to that of I175E-L-HN
(Table 3). As expected from its homology to L-HN at positions
TABLE 2. Mutation of I175E AV-HN at residues 193, 214, 219,
and 228 converts its phenotype to that of I175E L-HN
Strain Substitution(s)
Result fora:
Expression HAd NA Fusion
AV I175E 84.1  12.9 0.7  0.9 NDb 1.9  0.7
AV I175E, F193L 80.5  8.9 6.6  1.8 0.4  0.3 8.9  0.8
AV I175E, S214T,
V219I
95.6  6.7 5.7  1.3 0.1  0.1 9.1  6.1








103.4  2.6 53.8  3.8 6.0  2.2 141.6  11.4
L I175E 91.3  8.1 54.0  2.8 5.6  0.4 138.8  12.6
a Data are expressed as percentages of the corresponding wt HN protein. The
data for AV and L HN carrying only the I175E substitution are repeated from
Table 1 for convenience.
b ND, none detected.
FIG. 7. Sequence alignment of amino acids 175 to 230 in the HN glycoproteins of NDV strains AV, L, BC, and B1. Dashes indicate amino acid
identities. The four residues responsible for the phenotypic difference between the I175E AV-HN and I175E L-HN proteins are indicated in
boldface type. Sequence alignment was performed by using the Megalign program in Lasergene (DNASTAR).
TABLE 3. Effect of I175E substitutions in other NDV HN proteins
NDV strain
Result fora:
Expression HAd NA Fusion
BC 108.1  7.6 44.2  2.8 8.0  0.9 125.2  10.8
B1 103.2  12.4 24.4  5.1 1.9  0.8 6.2  1.8
a All data are expressed as percentages of wt AV-HN.
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214, 219, and 228, I175E mutated BC-HN has a similar phe-
notype, promoting fusion more than 25% more efficiently than
wt BC-HN.
Because of the leucine at position 193 in B1-HN, the phe-
notype of I175E mutated B1-HN is most accurately compared
to that of I175E mutated AV-HN carrying an F193L substitu-
tion (Table 2). Indeed, these two proteins promote fusion to
similar extents (6.2 and 8.9% of wt) (Tables 2 and 3). Thus, the
relationship between the phenotype of I175E-HN and residues
214, 219, and 228 is confirmed by analysis of naturally occur-
ring strains of the virus.
DISCUSSION
The promotion of membrane fusion by most paramyxovi-
ruses, including NDV, is dependent on the recognition of re-
ceptors by HN (18). Indeed, the strength of the HN-receptor
interaction can determine the extent of fusion (12, 23). How-
ever, lectins cannot replace HN in fusion (22). Also, MAbs to
antigenic sites 3 and 4 on NDV HN inhibit fusion but not
attachment (13, 14). Thus, HNs role in fusion clearly involves
something more than attachment. A second role for HN in
fusion is mediated by a virus-specific interaction between it and
the homologous F protein (8).
However, the relationship between HNs recognition of re-
ceptors and its interaction with F is not clear. At present, there
are two hypotheses. One is that the two proteins interact in-
tracellularly. In this model, HN is thought to maintain F in a
prefusion state until receptor recognition at the cell surface
induces a conformational change in F (29). An intracellular
interaction between the two proteins is supported by data
indicating that coexpression of HN with F alters the confor-
mation of the latter independent of receptor binding (19). On
the other hand, the demonstration that paramyxovirus HN or
F proteins tagged for retention in the endoplasmic reticulum
do not affect transport of the other protein argues against a
strong interaction between the two proteins, at least in this
cellular compartment (24). The alternative hypothesis pro-
poses that the HN-F interaction takes place only after the two
proteins have arrived at the cell surface, triggered by HNs
recognition of receptors (17). In this model, HN and F would
not interact either intracellularly or in the absence of receptor
binding. Of course, the two hypotheses are not mutually ex-
clusive, and the possibility exists that HN and F interact intra-
cellularly and the intracellular interaction is not fusion related.
HN proteins deficient in receptor recognition activity pro-
vide an opportunity to begin to discriminate between these two
mechanisms. If the two proteins do arrive at the cell surface
already associated with each other, the interaction would pre-
sumably take place independent of receptor recognition and
might even be stabilized in its absence. In this case, one would
expect attachment-deficient HN and F to be coimmunoprecipi-
tated from the cell surface. On the other hand, if the HN-F
interaction is triggered at the cell surface by HNs recognition
of receptors, this would result in a lack of HN-F complex
formation with an HN protein that fails to bind receptors.
By the introduction of single-amino-acid substitutions in the
NA active site, we have produced several NDV HN proteins
with single-amino-acid substitutions which lack detectable re-
ceptor recognition and fusogenic activity. Four of these mu-
tants, carrying substitutions of D198R, K236R, Y526L, and
E547Q, fail to interact with the NDV F protein in a coimmu-
noprecipitation assay. This strongly suggests that HN and F do
not arrive at the cell surface as a complex, at least one stable
under the conditions used for the coimmunoprecipitation. The
simplest explanation for these findings is that the HN-F inter-
action takes place at the cell surface, triggered by HNs rec-
ognition of receptors.
Among HN active site mutations, I175E appears to be
unique with respect to its relationship to F. Similar to the
others, this NA active site mutation virtually eliminates attach-
ment, NA, and fusion. However, unlike the others, the I175E
substitution converts HN to a form of the protein that interacts
with the F protein. This mutation separates the HN-F interac-
tion from receptor recognition. It apparently converts HN to a
fusion-ready conformation, though it is still unable to promote
fusion due to the lack of receptor recognition activity. The
reduced amount of I175E-HN coimmunoprecipitating with F
relative to wt HN indicates that the mutant complex is either
formed less efficiently or is less stable.
An interaction between I175E-AV-HN and F is consistent
with previous findings obtained with I175E-Kansas HN (1).
The latter mutant promotes fusion 50% more effectively than
the parent wt protein, despite exhibiting a more than 50%
reduction in HAd activity. It was postulated that the I175E
mutation in this protein acts by promoting a conformational
change in HN that is propagated to the dimer interface
through residue R174. This change in the dimer association
would then trigger the HN-F interaction necessary for fusion.
The mechanism by which this change in the structure of the
dimer converts HN to its F-interactive form is still not clear.
An understanding of this process is dependent on the precise
location of the site in HN that mediates the interaction with F.
It has been postulated that residues in the dimer interface,
exposed by the change in dimer association, may directly in-
teract with the F protein (1). Subsequently, mutations in the
HN dimer interface were identified that severely reduced fu-
sion (31). However, a mutational analysis of a domain at the
membrane-proximal end of the dimer interface has revealed
that loss of fusion-promoting activity correlates with a desta-
bilization of the interaction between HN and its receptor(s)
(2). This suggests that the fusion deficiency resulting from at
least some mutations in the dimer interface may be due to a
defect in receptor binding, rather than to a direct effect on
fusion.
Moreover, the possibility that dimer interface residues in the
globular domain could directly mediate the interaction with F
is inconsistent with data obtained by the analysis of chimeras
composed of segments from heterologous HN proteins. These
studies have shown that specificity for the homologous F pro-
tein segregates with the stalk region of HN (5, 32, 33). HN
chimeras with heterologously derived globular domains fuse
only with the F protein homologous to the HN stalk segment.
It is difficult to reconcile how dimer interface residues could
mediate specificity in these chimeras. They are neither con-
served nor located in the domain that determines F specificity.
To this end, it will be informative to determine the F-interac-
tive capacity of fusion-deficient HN carrying mutations in the
dimer interface. It is quite possible that changes at the dimer
interface could be part of the conformational change that takes
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place in HN in its conversion from a form that does not inter-
act with F to one that does.
A more recent peptide-based study suggests that the NDV
HN-F interaction is mediated by amino acids 124 to 152 in the
globular domain of HN and the membrane-proximal heptad
repeat in F (7). This finding may be consistent with the dem-
onstration that an NDV-hPIV3 HN chimera with 141 NDV-
derived N-terminal residues complements NDV F in fusion
and that one with only 125 NDV-derived N-terminal residues
does not (5). However, it is inconsistent with the failure of
several other chimeras with residues 124 to 152 intact to fuse
with NDV F. In fact, chimera CH1(6), which has NDV-
derived residues 120 to 571 intact, not only does not fuse with
NDV F but fuses quite efficiently with hPIV3 F (5). While it is
possible that the F-interactive domains in the NDV and hPIV3
HN proteins could be totally different, it seems unlikely that
the F-interactive residues reside in the stalk in one HN protein
and in the globular domain in the other. Clearly, to understand
the changes in HN that take place upon its conversion to the
F-interactive form, we must first more definitively identify the
region of the protein that mediates that interaction.
One question that can be answered is why I175E-mutated
HN fails to promote fusion, despite its efficient interaction with
the F protein. This appears to be the result of its lack of
receptor recognition activity, which is, in turn, a result of its
lack of NA activity. When the protein is supplied with NA
activity, it gains both significant attachment (11) and fusion-
promoting (Fig. 3) activities.
Thus, perhaps a potentially more informative question to
pose is why I175E-NDV HN lacks attachment activity in the
first place. NDV-Kansas, carrying the I175E mutation, retains
almost 50% of wt HAd activity and promotes fusion 50% more
efficiently than wt HN (1). We have shown that the amino acid
differences between the HN proteins from the two strains of
the virus that are responsible for their phenotypic differences
with respect to HAd and fusion are at positions 193, 214, 219,
and 228. When I175E-HN is further mutated at these positions
to those residues present in NDV-Kansas HN (F193L, S214T,
V219I, and N228S), the phenotype of the protein becomes
virtually indistinguishable from that of I175E-Kansas HN, in-
cluding enhanced fusogenic activity. The importance of these
residues to HN function was also supported by the analysis of
other strains of the virus.
Figure 8 shows the position in one monomer of each of these
residues relative to both residue I175 and the dimer interface.
All four residues reside at the interface, with residues 193 and
228 at one end and residues 214 and 219 at the other. With
their close proximity to the dimer interface, our data argue for
the importance of the integrity of the dimer interface to the
receptor recognition activity of NDV HN. This is consistent
with earlier conclusions based on a mutational analysis of res-
idues 218 to 226 (2). Substitutions at positions 220, 222, and
224 destabilize the interaction between HN and its receptor(s).
In addition, a V219A substitution results in a 60% enhance-
ment of HAd activity at 37°C relative to wt HN (2).
A role for residue 193 in the receptor recognition activity of
HN is also consistent with our previous findings. AV-HN is
unique in having a phenylalanine at residue 193, with leucine
being much more common at this position in NDV HN from
different strains (26). Substitutions at this position can have
profound effects on the strength of the HN-receptor interac-
tion. MAb-selected variants and temperature-sensitive mu-
tants of NDV-AV carrying an F193L or I substitution in HN
(often in combination with a mutation at I175) can be shown to
exhibit increased avidity for receptors and acquisition of the
ability to promote fusion from without, an activity normally
lacking in the parent wt NDV-AV virus (12, 15). This supports
the idea that residues 175 and 193 are functionally related.
FIG. 8. Locations of HN residues 193, 214, 219, and 228 relative to the dimer interface and residue 175. The figure shows a top view of the
Kansas HN dimer with the pH 6.5 structure of Crennell at al. (3). The two monomers in the dimer are shown in ribbon mode in magenta and cyan.
Important residues are shown in space-filling mode in one of the monomers. Residue 175 is shown in dark blue. Residues 193, 214, 219, and 228
are shown in yellow. The figure was generated with RasMol.
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In conclusion, we have shown that four different mutations
that abolish the receptor recognition activity of NDV HN also
abolish its ability to interact with the homologous F protein at
the cell surface. This is consistent with the idea that HN inter-
acts with F only after binding to its receptor. Also, we have
identified a point mutation (I175E) in the NA active site that
converts HN to a form that is capable of interacting with the
homologous F protein at the cell surface. The ability of the
latter to complement F in fusion is still dependent on its ability
to bind receptors. Thus, the I175E-HN-F complex could rep-
resent a fusion intermediate in which HN and F are associated
and primed for the promotion of fusion.
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